GRAPPA 2025 Collaborative Research Network Meeting: Difficult-to-Treat Psoriatic Arthritis and Future Strategies for Curing Psoriasis.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 42140636.
- Also identified by DOI 10.3899/jrheum.2026-0369.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Collaborative Research Network meeting in Bogotá, Colombia, experts in dermatology and rheumatology presented complementary perspectives on the future of psoriatic disease management. Dr. Andrew Blauvelt introduced innovative approaches to achieving long-term remission or a cure for psoriasis, focusing on early intervention and "knockout" therapies with high-dose interleukin 23 inhibitors. Dr. Philip Mease presented evolving concepts in difficult-to-treat and complex-to-manage psoriatic arthritis, emphasizing the need for formal definitions and the growing role of dual therapy strategies. This session reflected a shift toward a more personalized, proactive, and multidisciplinary strategy to address unmet needs in psoriatic disease.